Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Verrica Pharmaceuticals (VRCA) Enterprise Value (2021 - 2025)

Verrica Pharmaceuticals has reported Enterprise Value over the past 5 years, most recently at -$30.1 million for Q4 2025.

  • Quarterly results put Enterprise Value at -$30.1 million for Q4 2025, up 34.93% from a year ago — trailing twelve months through Dec 2025 was -$30.1 million (up 34.93% YoY), and the annual figure for FY2025 was -$30.1 million, up 34.93%.
  • Enterprise Value for Q4 2025 was -$30.1 million at Verrica Pharmaceuticals, down from -$21.1 million in the prior quarter.
  • Over the last five years, Enterprise Value for VRCA hit a ceiling of -$15.4 million in Q2 2025 and a floor of -$84.3 million in Q3 2023.
  • Median Enterprise Value over the past 5 years was -$33.4 million (2022), compared with a mean of -$39.1 million.
  • Biggest five-year swings in Enterprise Value: crashed 159.6% in 2023 and later surged 72.72% in 2024.
  • Verrica Pharmaceuticals' Enterprise Value stood at -$15.8 million in 2021, then tumbled by 117.58% to -$34.3 million in 2022, then plummeted by 102.92% to -$69.5 million in 2023, then skyrocketed by 33.38% to -$46.3 million in 2024, then skyrocketed by 34.93% to -$30.1 million in 2025.
  • The last three reported values for Enterprise Value were -$30.1 million (Q4 2025), -$21.1 million (Q3 2025), and -$15.4 million (Q2 2025) per Business Quant data.